Search results
Results from the WOW.Com Content Network
Metyrapone, sold under the brand name Metopirone, is a medication which is used in the diagnosis of adrenal insufficiency and occasionally in the treatment of ...
Aminoglutethimide (AG), sold under the brand names Elipten, Cytadren, and Orimeten among others, is a medication which has been used in the treatment of seizures, Cushing's syndrome, breast cancer, and prostate cancer, among other indications.
Metyrapone and ketoconazole are often preferred as first-line pharmacological treatments, either as monotherapy or in combination, due to their efficacy in controlling hypercortisolemia. [2] However, careful monitoring is essential during treatment, as these drugs can potentially cause side effects and, in some cases, lead to adrenal ...
Cushing's syndrome is a collection of signs and symptoms due to prolonged exposure to glucocorticoids such as cortisol. [4] [9] [10] Signs and symptoms may include high blood pressure, abdominal obesity but with thin arms and legs, reddish stretch marks, a round red face due to facial plethora, [11] a fat lump between the shoulders, weak muscles, weak bones, acne, and fragile skin that heals ...
For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medication that provides an alternative to addictive opioids for patients looking to manage ...
The 17 Best Retinol Creams Worth Adding to Your Skin Care Routine. Show comments. Advertisement. Advertisement. In Other News. Finance. Finance. Benzinga.
Committee members at the National Academies of Science, Engineering and Medicine said in a September report that nearsightedness has become an “evolving epidemic” that requires more research ...
Most chapters within a unit are organized as follows, although there are some exceptions. Nursing-sensitive patient outcomes (NOC) are discussed before interventions. This is because in the sequence of clinical reasoning desired outcomes are identified prior to selection of interventions to achieve the outcomes.